News | August 10, 2024
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Oteseconazole Capsules were found to be safe and more effective than fluconazole
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
